Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MADIT-I and MADIT-II.

Arthur J Moss1

  • 1Department of Medicine, University of Rochester Medical Center, Rochester, New York 14542, USA. heartajm@heart.rochester.edu

Journal of Cardiovascular Electrophysiology
|September 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low magnetic fields stimulate cardiac mitochondrial bioenergetics with a bell-shaped response: Possibly via a radical pair mechanism.

Computational and structural biotechnology journal·2025
Same author

Heritability in genetic heart disease: the role of genetic background.

Open heart·2019
Same author

Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction.

European journal of heart failure·2018
Same author

Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients.

JACC. Clinical electrophysiology·2018
Same author

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.

Journal of the American College of Cardiology·2018
Same author

Risk Stratification of Type 2 Long-QT Syndrome Mutation Carriers With Normal QTc Interval: The Value of Sex, T-Wave Morphology, and Mutation Type.

Circulation. Arrhythmia and electrophysiology·2018

The implantable cardioverter defibrillator (ICD) saves lives in high-risk coronary heart disease patients. Prophylactic ICD therapy improves survival in ischemic cardiomyopathy, supporting its use in eligible patients.

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Trials

Background:

  • The MADIT-I study demonstrated the life-saving potential of implantable cardioverter defibrillators (ICDs) in high-risk coronary heart disease patients.
  • The MADIT-II study established that prophylactic ICD therapy significantly improves survival in patients with ischemic cardiomyopathy.

Purpose of the Study:

  • To summarize the findings of the MADIT-I and MADIT-II trials regarding implantable cardioverter defibrillator (ICD) therapy.
  • To determine the indications for ICD therapy in patients with coronary heart disease and left ventricular dysfunction.

Main Methods:

  • Review of randomized trial data from MADIT-I and MADIT-II.
  • Analysis of survival data in patients receiving prophylactic ICD therapy.

Related Experiment Videos

Main Results:

  • The MADIT-I trial confirmed ICDs save lives in high-risk coronary heart disease patients.
  • The MADIT-II trial showed prophylactic ICDs improve survival in ischemic cardiomyopathy without arrhythmia screening.
  • Combined evidence supports ICD use in coronary patients meeting MADIT-I or MADIT-II criteria.

Conclusions:

  • Implantable cardioverter defibrillator (ICD) therapy is indicated for coronary patients meeting MADIT-I or MADIT-II eligibility criteria.
  • ICD therapy offers significant survival benefits for high-risk patients with coronary heart disease and left ventricular dysfunction.
  • Exclusion criteria include major noncardiac comorbidity.